Prostate cancer (PCa) contains phenotypically and functionally distinct cells, and this
cellular heterogeneity poses clinical challenges as the distinct cell types likely respond …

Cancer progression is characterized and driven by gradual loss of a differentiated
phenotype and gain of stem cell-like features. In prostate cancer (PCa), androgen receptor …

Androgen receptor (AR) regulation pathways are essential for supporting the growth and
survival of prostate cancer cells. Recently, sub-populations of prostate cancer cells have …

The prostate gland is highly dependent on androgens for its development, growth and
function. Consequently, the prostatic epithelium predominantly consists of androgen …

The androgen deprivation therapy (ADT) to systematically suppress/reduce androgens
binding to the androgen receptor (AR) has been the standard therapy for prostate cancer …

Prostate cancer (PCa) remains one of the most prevalent malignancies affecting men in the
western world. The etiology for PCa development and molecular mechanisms underlying …

Prostate cancer (PCa) is the most common cause of malignancy in males and the second
leading cause of cancer mortality in United States. Current treatments for PCa include …

Prostate cancer is one of the most commonly diagnosed cancers in men, and androgen
deprivation therapy still represents the primary treatment for prostate cancer patients. This …

Androgen receptor (AR), a ligand-dependent nuclear transcription factor and a member of
steroid hormone receptor family, plays an important role in prostate organogenesis by …

Androgen deprivation therapy (ADT) is standard frontline therapy for metastatic prostate
cancer. However, prostate cancer progresses to a castrate-resistant state. The response of …